Active, not recruitingPhase 1NCT06432140
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency
Studying Aromatic L-amino acid decarboxylase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Principal Investigator
- Xiumin Wang, MDShanghai Children's Medical Center, affiliated to Shanghai Jiao Tong University School of Medicine
- Intervention
- VGN-R09b injection(genetic)
- Enrollment
- 13 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2024 – 2030
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06432140 on ClinicalTrials.govOther trials for Aromatic L-amino acid decarboxylase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT05765981An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE2NCT04903288A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric ParticipantsPTC Therapeutics
- RECRUITINGPHASE1NCT02852213A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric PatientsKrzysztof Bankiewicz
See all trials for Aromatic L-amino acid decarboxylase deficiency →